Crispr Therapeutics Ord Shs (CRSP)
$84.11 4.41 (5.53%)
18:32 EDT CRSP Stock Quote Delayed 30 Minutes
Previous Close $84.11
Market Cap 3.94B
PE Ratio -
Volume (Avg. Vol.) 1.57M
Day's Range 79.13 - 85.00
52-Week Range 32.30 - 85.00
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ord Shs News
- From InvestorPlace
- From the Web
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
Verizon CEO Hans Vestberg explains what practical benefits consumers and businesses will receive from Verizon 5G, addresses why his company pulled advertising from Facebook and doubles down on his decision not to acquire media companies -- though he leaves the door open for eventual cable consolidation.
Navellier RatingsPowered by Portfolio Grader